Harmony Biosciences Holdings, Inc.
corporate_fare Company Profile
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for HRMY at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Harmony Biosciences Reports Strong 2025 Results, Secures Pediatric Cataplexy Approval for WAKIX, and Advances Pipeline
- Harmony Biosciences Reports Strong 2025 Revenue, Reiterates 2026 Guidance, Despite Q4 Profit Decline
- Harmony Biosciences Guides WAKIX to Blockbuster Status with $1B+ 2026 Revenue, Advances Robust Late-Stage Pipeline
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$868.45M
Net Income
$158.69M
Diluted EPS
$2.71
Op. Cash Flow
$348.2M
Free Cash Flow
$347.89M
Gross Profit
$670.11M
Operating Income
$208.47M
Cash & Equivalents
$752.5M
Total Debt
$163.66M
Debt / Equity
0.19×
Net Margin
18.3%
Shares Outstanding
57.73M sh
Source: 10-K · filed 2026-02-24 · accession 0001104659-26-018859
show_chartPrice Chart
Loading chart...
feed HRMY - Filings & News (Page 2)
HRMY
Feb 24, 2026, 8:16 AM EST
Price at Filing:
$26.41
Real-time Price:
$32.43
Change:
+$6.02 (+23%)
Market Cap:
$1.914B
HRMY
Feb 24, 2026, 8:10 AM EST
Harmony Biosciences Reports Strong 2025 Revenue, Reiterates 2026 Guidance, Despite Q4 Profit Decline
Price at Filing:
$26.41
Real-time Price:
$32.43
Change:
+$6.02 (+23%)
Market Cap:
$1.914B
HRMY
Jan 12, 2026, 8:20 AM EST
Price at Filing:
$38.44
Real-time Price:
$32.43
Change:
-$6.01 (-16%)
Market Cap:
$1.914B